The 4S pathway is the most studied bioprocess for the removal of the recalcitrant sulfur of aromatic heterocycles present in fuels. It consists of three sequential functional units, encoded by the dszABCD genes, through which the model compound dibenzothiophene (DBT) is transformed into the sulfur-free 2-hydroxybiphenyl (2HBP) molecule. In this work, a set of synthetic dsz cassettes were implanted in Pseudomonas putida KT2440, a model bacterial "chassis" for metabolic engineering studies. The complete dszB1A1C1-D1 cassette behaved as an attractive alternative -to the previously constructed recombinant dsz cassettes -for the conversion of DBT into 2HBP. Refactoring the 4S pathway by the use of synthetic dsz modules encoding individual 4S pathway reactions revealed unanticipated traits, e.g., the 4S intermediate
Introduction
Crude oils contain undesirable contaminant molecules, such as thiophenic aromatics compounds, which have a negative impact on oil processing and pose serious environmental threats (Soleimani et al., 2007) . A wide spectrum of desulfurization technologies have been developed to remove sulfur mainly from finished refinery products (Stanislaus et al., 2010) . Hydrodesulfurization (HDS) treatment has proved to be the common technology of choice to reduce the level of sulfur in crude oil products.
Significant environmental, technical and economic limitations have been reported in applying the HDS process (Babich and Moulijn, 2003) .
During the past 30 years, research to develop alternative desulfurization technologies resulted in a biotechnological strategy to eliminate sulfur from thiophenic compounds (biodesulfurization (BDS)) via serial reactions known as the 4S pathway (Gray et al., 2003; Gupta et al., 2005; Kilbane, 2006; Monticello, 2000; Nuhu, 2013; Xu et al., 2009 ). This pathway was firstly reported in the gram-positive bacterium
Rhodococcus erythropolis IGTS8 (Gallagher et al., 1993) , but the 4S pathway has been also found in other bacteria (Duarte et al., 2001; Kilbane, 2006; Mohebali and Ball, 2008) .
The 4S pathway provides a nondestructive oxidative process used by the cells to obtain the sulfur required for growth, which involves the transformation of dibenzothiophene (DBT), the model compound for sulfur heterocycles present in oil and refractory to HDS, into 2-hydroxybiphenyl (2HBP) and sulfite ( Fig. 1A ) (Gallagher et al., 1993) . Sulfite is further assimilated via its oxidation into sulfate by a sulfite oxidoreductase (Aggarwal et al., 2012) . In the 4S pathway, DBT undergoes three successive oxidation steps leading to the formation of DBT-sulfoxide (DBTO), DBT-sulfone (DBTO 2 ) and 2HBP-sulfinate (HBPS) mediated by two monooxygenases (DszC and DszA), followed by a hydrolytic step for sulfur removal as sulfite, and formation of 2HBP, which is mediated by a desulfinase (DszB). The three oxidation steps require reducing equivalents (FMNH 2 ) supplied by a flavin-reductase (DszD) (Fig. 1A ) (Gray et al., 1996) . The genetics of the 4S pathway has been elucidated in R. erythropolis IGTS8 being coded by three megaplasmid-born genes (dszABC) and one chromosomalborn gene (dszD) (Fig 1B) (Gray et al., 1996) .
Attempts to remove sulfur from crude oil based on the 4S pathway have identified two major technical bottlenecks, which need to be overcome to develop a feasible bioprocess for sulfur removal in the oil industry. These major bottlenecks are bioprocess-related hurdles to develop a continuous bioprocess, and biocatalyst-related limitations to develop robust biocatalysts with a high catalytic desulfurization rate.
Since low amounts of sulfur are required for bacterial growth, and the native regulation of dsz gene expression is sulfur-dependent (Li et al., 1996) , the dsz genes are expressed at low level in almost all naturally occurring bacteria harboring the 4S pathway, which leads to low rates of DBT desulfurization from an industrial point of view (Kilbane, 2006) . Moreover, decay of the BDS activity due to the accumulation of the sulfur-free end product 2HBP in bacterial biocatalysts has been reported (Abin-Fuentes et al., 2013) . It has been shown that bacteria harboring identical dsz genes provide different BDS rates due to the influence of the host metabolism (Kilbane, 2006) . To enhance the catalytic rate of DBT desulfurization, the genetic determinants of the 4S pathway have been the target for enormous genetic boosting strategies, including: i) expression under control of strong promoters that alleviate sulfur-dependent transcriptional regulation ; ii)
removal of dszAB gene overlap, iii) cloning of multiple copies of dsz genes; iv) cloning of more efficient versions of dszD; v) genetic rearrangement of dsz genes to have better expression and optimized catalytic activities; vi) enhancing the level of expression of dszB, that encodes the rate-limiting step of the 4S pathway, by mutating its 5 ′ untranslated region; vii) adding a synthetic gene coding for a polypeptide of sulfurcontaining amino acids to increase sulfur consumption; viii) cloning dsz genes in different robust hosts; and ix) gene shuffling as well as other directed evolution methods on the Dsz enzymes (Kilbane, 2006; Li et al., 2008; Ma et al., 2006; Shavandi et al., 2009; Wang et al., 2011) . Despite all these successful trials to produce genetically improved biocatalysts, so far, none of the deployed gene manipulation techniques has resulted in a BDS rate meeting the industrial requirement for the development of a commercial BDS process (Boniek et al., 2015; Kilbane, 2006) . Moreover, no real efforts have been taken to solve HBPS and 2HBP-related feedback inhibition of the BDS process (Abin-Fuentes et al., 2013) . Since the 4S pathway consists of three serial and irreversible functional modules (Fig. 1A ) that can be successfully expressed in several heterologous hosts unable to desulfurize DBT (Diaz and Garcia, 2010) , it constitutes an ideal target for improvement through synthetic biology and metabolic engineering approaches.
In the present study, we developed a collection of synthetic dsz cassettes and "à la carte" bacterial consortia to overcome bottlenecks of the 4S pathway and enhance DBT bioconversions into unattainable chemicals.
Materials and methods

Chemicals
Chemicals used in this work, including DBT and DBTO 2 , were from Sigma.
2HBP was purchased from Fluka. HBPS was synthesized as described in previous studies (Hanson and Kemp, 1981; Oldfield et al., 1997) .
Bacterial strains, plasmids, and growth conditions
Bacterial strains and plasmids used in this work are listed in Table 1 . Bacterial strains were grown in lysogeny broth (LB) medium (Sambrook and Russell, 2001) (Martin et al., 2004) . When appropriate, antibiotics were added at the following concentrations: ampicillin (100 μg mL -1 ), kanamycin (50 μg mL -1 ), gentamicin (10 μg mL -1 ), and tetracycline (10 μg mL -1 ).
Molecular biology techniques
Standard molecular biology techniques were performed as previously described (Sambrook and Russell, 2001) . Plasmid DNA was prepared with a High Pure plasmid isolation kit (Roche Applied Science). DNA fragments were purified with Gene-Clean Turbo (Q-BIOgene). Oligonucleotides were supplied by Sigma. All cloned inserts and DNA fragments were confirmed by DNA sequencing with fluorescently labeled dideoxynucleotide terminators (Sanger et al., 1977) (Sambrook and Russell, 2001 ). The protein concentration was determined by the method of Bradford (Bradford, 1976 ) using bovine serum albumin as the standard. Nucleotide sequence analyses were done at the National Center for Biotechnology Information (NCBI) server (http://www.ncbi.nlm.nih.gov).
Construction of dsz cassettes
A complete dszB1A1C1-D1 cassette was synthesized by ATG:biosynthetics GmbH (Merzhausen, Germany) and supplied as a 4.6 kb EcoRI/XbaI DNA fragment (the nucleotide sequence of this cassette was submitted to GenBank with Accession number KR270527) cloned into the EcoRI/XbaI double digested pUC-derived pGH vector, or into the broad-host range plasmid pIZ1016 (Table 1) , giving rise to plasmids pGHdszB1A1C1-D1 (Table 1 ) and pIZdszB1A1C1-D1 (Table 1 , Fig. 1C ), respectively.
The dszB1A1-D1, dszC1-D1 and dszB1 cassettes were constructed by StuI-, XhoI-and ClaI-digestion and further re-ligation of the pIZdszB1A1C1-D1 plasmid, respectively, giving rise to plasmids pIZdszB1A1-D1, pIZdszC1-D1 and pIZdszB1 ( This resting cells preparation was used for the BDS assays, which were carried out in an orbital shaker at 30 ºC and 200 rpm after adding 4S compounds (DBT, DBTO 2 or HBPS). Samples were collected periodically and, unless otherwise specified, extracted with an equal volume of acetonitrile for HPLC analysis of substrate consumed and product(s) generated after centrifugation at 14000 x g for 10 min. To check the extracellular location of some 4S-pathway intermediates, resting cells were centrifuged at 14000 x g for 10 min and the supernatant was extracted with acetonitrile and analyzed by HPLC. Three/four different biological samples were used to calculate substrate consumption and intermediates/product formation in all experiments reported in this work.
DszB assays in cell extracts
For the DszB assays using crude cell extracts, P. putida KT2440 (pIZdszB1) cells were grown as detailed above (section 2.5), washed twice with 0.9% NaCl and resuspended in 50 mM HEPES buffer pH 8.0 at an A 600 of 20, and disrupted by passage through a French press operated at a pressure of 20000 psi. Cell debris were removed by centrifugation at 16000 g for 20 min at 4ºC, and the resulting supernatant was used as crude cell extract. DszB assays were carried out after adding HBPS to the cell extract in a 100 mL Erlenmeyer flask that was incubated in an orbital shaker at 30 ºC and 200
rpm. Samples were collected periodically and extracted with an equal volume of acetonitrile for analysis of HBPS consumed and 2HBP generated.
Flavin reductase assay
Flavin reductase activity was measured in crude cell extracts of P.putida KT2440 (pIZdszB1A1C1-D1) and P. putida KTH2 (pESOX3) strains were obtained as detailed above (section 2.6). Flavin reductase activity was detected by a spectrophotometric assay measuring the oxidation of NADH at 340 nm (ε= 6.22·10 -3 M -1 cm -1 ) (Galan et al., 2000a) . The reaction consists of 200 µM NADH, 10 µM FMN in 25 mM sodium phosphate buffer pH 7.4 containing 100 mM NaCl and 0.5 mM DTT (Gray et al., 1996) , in a final volume of 0.7 mL. The assay was initiated by adding 0.03 mL of the enzyme extract and was run at 22ºC during a controlled period of time.
Analytical methods
Absorbance at 600 nm (A 600 ) was measured using a Shimadzu UV-Vis spectrophotometer (model UV mini 1240 Calibrations were performed using highly purified standards of each compound.
Results and discussion
The dszB1A1C1-D1 cassette enhances conversion of DBT into 2HBP
Based on the sequence of the R. erythropolis IGTS8 dsz genes (Gray et al., 1996; Oldfield et al., 1997; Piddington et al., 1995; Tao et al., 2011) , we have synthesized modified genes, called dszA1, dszB1, dszC1 and dszD1, to engineer a synthetic dszB1A1C1-D1 cassette (Fig. 1C) . This was achieved with the following: i) the native dszABC operon was rearranged to avoid overlapping genes and to increase the expression of the dszB gene that encodes the rate-limiting step of the 4S pathway; ii) the native gene expression signals that are under sulfur-dependent control were substituted by optimized transcriptional (based on the lacI q /P tac and lacI q /P lac regulatory couples) and translational (consensus ribosome-binding site, optimized codon usage) signals for
Pseudomonas strains that are not subject of sulfate-dependent inhibition; iii) the Y63F amino acid substitution -previously reported to enhance the activity and stability of the DszB desulfinase (Ohshiro et al., 2007) -was engineered in the synthetic dszB1 gene; iv) a synthetic dszD1gene -encoding the flavin reductase needed for the two monooxygenase reactions of the 4S pathway and that is not linked to the dszABC genes in strain IGTS8 (Fig. 1B) -was included in the dsz cassette. To avoid the potential toxic effect of an increased expression of the dszD gene (Galan et al., 2000a) , it was arranged as an independent operon under control of the weak P lac promoter and separated from the dszB1A1C1 operon by a strong transcriptional terminator of the lambda phage (Fig. 1C) . The modularity of the dsz synthetic cassette was facilitated by removing some restriction enzyme sites present in the native dsz genes and by adding other sites that allow the easy removal/insertion of the synthetic genes in different vectors and under control of different regulatory elements (Fig. 1C) . The dszB1A1C1-D1 gene cassette was cloned and expressed in a broad-host range vector, plasmid pIZ1016, able to replicate in a wide variety of gram-negative bacteria (Moreno-Ruiz et al., 2003) , giving rise to plasmid pIZdszB1A1C1-D1 ( Fig. 1C ; Table 1 ).
The functionality of the dszB1A1C1-D1 cassette was tested in P. putida KT2440, a bacterium that has been proposed as an optimal bacterial "chassis" endowed with metabolic, physiological and stress-endurance traits of biotechnological interest (Nikel et al., 2014) . In a resting cell process, P. putida KT2440 (pIZdszB1A1C1-D1) converted all DBT to nearly stoichiometric amounts of 2HBP after 180 min incubation ( Fig. 2) , hence demonstrating that the dszB1A1C1-D1 cassette was fully and efficiently functional. When we compared these results with those achieved by using P. putida KTH2 (pESOX3), a recombinant P. putida strain expressing the native dszABC genes (Galan et al., 2000a), we observed an almost 3-fold increase in the production of 2HBP (Fig. 2B) , suggesting that the dszB1A1C1-D1 synthetic module behaves as an attractive and efficient alternative to previous recombinant dsz cassettes.
The rate of consumption of DBT was lower when using the P. putida KT2440 (pIZdszB1A1C1-D1) biocatalyst than when using the P. putida KTH2 (pESOX3) strain ( Fig. 2A ), suggesting that a higher rate of DBT consumption leads to a lower efficiency of 2HBP formation, as previously pointed out (Reichmuth et al., 2000) . Since DBT removal is due to the DszC activity (Fig. 1A) , and this monooxygenase depends on the FMNH 2 cellular levels, the flavin reductase activity levels of the host cell become critical for an efficient initial oxidation of DBT. In this sense, whereas P. putida in P. putida KT2440 (pIZdszB1A1C1-D1). Thus, these results confirm a significantly higher flavin reductase activity in the P. putida KTH2 (pESOX3) strain which, in turn, is in agreement with the higher DBT removal rate observed with this biocatalyst ( Fig.   2A ). Although the molecular basis of this finding is still unknown, the fast oxidation of DBT may lead to the transient accumulation of intermediates that act as Dsz enzyme inhibitors, causing a lower 2HBP formation (Abin-Fuentes et al., 2013) . All of these results suggest that the tight control of the expression of the dszD flavin reductase gene in the dszB1A1C1-D1 cassette is critical to designing an efficient process for complete bioconversion of DBT into 2HBP.
Design of a collection of functional dsz cassettes for bioconversions of 4S-pathway compounds: identifying unanticipated bottlenecks
A major bottleneck of the current 4S-pathway expressing biocatalysts is the observed reduction of DBT oxidation when 2HBP accumulates (Abin-Fuentes et al., 2013) , hence suggesting that the BDS process could be improved by engineering an artificial 4S pathway, where the enzymatic steps were compartmentalized in different host biocatalysts for individual optimization, and to avoid exposure of the Dsz enzymes to the inhibitory effects of the 4S pathway intermediates. To accomplish this unprecedented approach in BDS, three synthetic DNA cassettes containing single dsz genes (dszB1), or combinations of two (dszA1-D1, dszC1-D1) or three (dszA1C1-D1, dszB1A1-D1) dsz genes, were constructed (Fig. 1C) . These dsz cassettes were introduced into P. putida KT2440 and their functionality was studied in resting cell assays.
The P. putida KT2440 cells expressing the dszC1-D1 cassette completely converted DBT into DBTO 2 in about 30 min (Fig. 3A) . Remarkably, the rate of DBT removal was higher with a biocatalyst expressing the dszC1-D1 cassette (Fig. 3A) than with a biocatalyst expressing the complete dszB1A1C1-D1 module ( Fig. 2A) , pointing out the inhibitory effect of 4S-pathway compounds on the activity of DszC monooxygenase (Abin-Fuentes et al., 2013) . To study further this inhibitory effect in vivo, we monitored the conversion of DBT into HBPS by using the dszA1C1-D1 cassette (Fig. 1C) . As shown in figure 4A , a high initial removal rate of DBT was observed, but the reaction slowed down after 15 min and 30% of the substrate (DBT) remained in the medium at the end of the resting cell process. These results, therefore, The dszA1-D1 cassette (Fig. 1C ) completely converted DBTO 2 into HBPS in about 120 min (Fig. 3B) . A faster removal of DBTO 2 was observed by using the dszB1A1-D1 cassette (Fig. 1C ) that is also able to convert HBPS into 2HBP (Fig. 4B) .
Thus, these results reveal a previously unknown inhibitory effect of HBPS on the activity of the DszA monooxygenase.
Interestingly, when 25 µM HBPS was added to P. putida KT2440 (pIZdszB1) cells, no production of 2HBP was observed even after 180 min of incubation of the resting cells, and all HBPS was recovered in the extracellular medium (Fig. 5A) ,
suggesting that the dszB1 module (Fig. 1C) was not functional in a resting cell assay. To confirm that this behavior was due to a lack of uptake of HBPS inside the biocatalyst rather than to an inactive DszB1 enzyme, cell free crude extracts of P. putida KT2440 (pIZdszB1) were used, and an efficient conversion of HBPS into 2HBP was observed (Fig. 5B) This observation is in agreement with the fact that HBPS is easily secreted to the medium and, as indicated above, unable to enter again into the cells for its further biotransformation to 2HBP. In summary, these results highlight the importance of HBPS secretion as a previously unrecognized bottleneck that may reduce the conversion of DBT into 2HBP when using whole cell biocatalysts. Thus, it seems critical to coordinate the production of HBPS with its transformation to 2HBP, since the overaccumulation of HBPS in the cytoplasm may conduct to its premature release to the medium.
Enhancing conversion of DBT into 2HBP by engineering synthetic bacterial consortia
As suggested above, both formation and consumption of HBPS must be precisely programmed within a single biocatalyst. Moreover, we have demonstrated that the rate of DBT and DBTO 2 removal can be significantly enhanced, with respect to that obtained with the complete dszB1A1C1-D1 synthetic module, by using the dszC1-D1 (Fig. 3A) and dszB1A1-D1 (Fig. 4B) cassettes, respectively. Hence, to increase the bioconversion of DBT into 2HBP we designed an artificial 4S pathway based on the construction of synthetic bacterial consortia. This approach of sequential desulfurization using segregated steps of the 4S pathway should also avoid the inhibitory effect that HBPS and 2HBP exert on DszC in monocultures (Abin-Fuentes et al., 2013).
A first bacterial consortium was made of P. putida KT2440 (pIZdszC1-D1) cells, which convert DBT into DBTO 2 (Fig. 3A) , and P. putida KT2440 (pIZdszB1A1-D1) cells, which convert DBTO 2 into 2HBP (Fig. 4B) . We have observed that a high rate of DBT consumption leads to a lower production of 2HBP due to the formation of HBPS that inhibits the DszC and DszA monooxygenases (Fig. 4) ; therefore to generate the most efficient consortium we tested different ratios of both biocatalysts for optimizing the rate of DBTO 2 formation and consumption. As shown in Fig. 6A , when the consortium was arranged as a P. putida KT2440 (pIZdszC1-D1): P. putida KT2440 (pIZdszB1A1-D1) cell ratio of 2:1, the efficiency of 2HBP formation (about 15%) was even lower than that obtained when using the P. putida KT2440 (pIZdszB1A1C1-D1) biocatalyst (about 20%). This result is in agreement with our previous observation that a fast oxidation of DBT to DBTO 2 would turn into a high amount of HBPS that will become toxic and block the whole Dsz pathway. On the contrary, when we shifted the cell ratio in the consortium by increasing the amount of the P. putida KT2440 (pIZdszB1A1-D1) biocatalyst with respect to that of the P. putida KT2440 (pIZdszC1-D1) biocatalyst, we observed a higher 2HBP formation efficiency than with a similar amount of the P. putida KT2440 (pIZdszB1A1C1-D1) biocatalyst, reaching values of 2HBP formation up to 50% at a cell ratio of 1:4 (Fig. 6A) . Thus, these results reveal that generating an artificial 4S pathway by combining the dszC1-D1 and dszB1A1-D1 cassettes in a balanced synthetic bacterial consortium is a new and promising strategy to increase bioconversion of DBT into 2HBP.
We have shown above that the dszB1A1-D1 cassette is able to efficiently oxidize DBTO 2 but it only synthesizes 35% 2HBP due to the fact that a significant amount of HBPS is secreted to the culture medium and then it cannot enter the cell anymore (Fig.   4B ). To overcome this bottleneck for improving further the efficiency of the 4S artificial pathway, it would be desirable to recover and channel the secreted HBPS for 2HBP
formation. Since the dszB1 cassette that converts HBPS into 2HBP does not require reducing power and, therefore, it is fully active in cell-free extracts (Fig. 5B) , we tested the combination of cell-free extracts obtained from the dszB1 module with the optimized P. putida KT2440 (pIZdszC1-D1): P. putida KT2440 (pIZdszB1A1-D1)
(1:4) bacterial consortium and also with P. putida KT2440 carrying the complete cassette (pIZdszB1A1C1-D1). As shown in Fig. 6B , when DszB1 extracts were added to the target bacterial consortium an almost full conversion of DBT into 2HBP was achieved. However, when DszB1 extract was added to the complete cassette, it was not possible to achieve a complete conversion (Fig. 6B ) since about 30 µM DBT was still remaining in the medium probably due to the inhibitory effect of HBPS and 2HBP on the DszC activity. Taken together all these results, we can conclude that the rational combination of appropriated dsz cassettes in synthetic bacterial consortia becomes a suitable alternative to the use of naturally existing or recombinant dsz pathways (Diaz and Garcia, 2010; Galan et al., 2000a; Gray et al., 2003; Kilbane, 2006; Li et al., 2008; Ma et al., 2006; Xu et al., 2009 ) for developing a process toward the bioproduction of 2HBP from DBT.
The specific desulfurization activity reached with the microbial consortia presented in this work is 23 μmol 2HBP /g DCW/h. This value is the highest of those described previously in the literature, i.e., 21.6 (Davoodi et al., 2010) , 11.9 (Martín et al., 2005 ), 8.9 (del Olmo et al., 2005 , 3.6 (Alves and Paixao, 2014) and 2.1 (Rashtchi et al., 2006) μmol 2HBP produced/g DCW/h, when using microbial resting cell cultures in aqueous phase. Further research to increase bioconversion efficiencies may be focused on the problem of desulfurizing HBPS in medium broth. Several strategies can be addressed and may imply either: i) the use of immobilized cell-free extracts or purified DszB enzyme into, for instance, magnetic beads would allow its recovery for a continuous BDS process; ii) the development of bioreactors with membranes coated with DszB; iii) the development of a bacterial chassis permeable to HBPS which could allow the uptake of HBPS into the cells, e.g. engineering a membrane channel similar to those described for hydrocarbons or phenols uptake (Parales et al., 2008) ; iv)
engineering an active extracellular DszB enzyme anchored to the bacterial surface of the biocatalyst.
Developing bacterial synthetic consortia for the production of HBPS
Segregating the steps of the 4S pathway can be used to terminate the BDS at the level of some intermediates, which are unattainable by monocultures and can be used as precursors for other petrochemicals (e.g., DBTO 2 and HBPS). Since HBPS is not commercially available and it is of biotechnological interest for the chemical synthesis of biosurfactants (Monticello, 2000; Xu et al., 2009) , we have used our synthetic cassettes to develop an efficient cellular system for the conversion of DBT into HBPS.
As shown in Fig. 4A , a biocatalyst expressing the dszA1C1-D1 cassette is able to convert DBT into HBPS but this conversion is far from being complete due to the inhibitory effects of HBPS on the DszC/DszA monooxygenases. Therefore, we
proposed that the combination of the dszC1-D1cassette, that efficiently converts DBT into DBTO 2 (Fig. 3A) , with the dszA1-D1 cassette, which converts DBTO 2 into HBPS (Fig. 3B) , by generating a synthetic bacterial consortium made of the P. putida (pIZdszC1-D1) and P. putida (pIZdszA1-D1) biocatalysts, could be a rational strategy to enhance HBPS production. Hence, we tested different ratios of both biocatalysts in resting cell experiments to settle the most efficient bacterial consortium. As shown in Fig. 7 , when we increased the amount of the P. putida KT2440 (pIZdszA1-D1)
biocatalyst with respect to that of the P. putida KT2440 (pIZdszC1-D1) biocatalyst, the conversion of DBT to HBPS was enhanced, and we already achieved full conversion at a dszC1-D1:dszA1-D1 ratio of 1:1. These results demonstrate that the compartmentalization of the monooxygenase-dependent steps of the 4S pathway for DBT desulfurization in two different cell biocatalysts and their further combination to generate an artificial bacterial consortium constitutes a successful strategy toward the efficient conversion of DBT into the high added value HBPS compound.
Conclusions
In this work, a new functional dszB1A1C1-D1 synthetic cassette has been designed, demonstrating that it behaves as an attractive and efficient alternative to the previously constructed recombinant dsz cassettes (Diaz and Garcia, 2010; Galan et al., 2000a; Gray et al., 2003; Kilbane, 2006; Li et al., 2008; Ma et al., 2006; Xu et al., 2009) for the bioconversion of DBT into 2HBP. We have shown that a higher rate of DBT consumption leads to a lower efficiency of 2HBP formation, which agrees with the fact that some 4S intermediates, such as HBPS, behave as inhibitors of the DszC and DszA enzymes. Thus, a tight control of the expression of the dszD flavin reductase gene becomes critical to control the activity of the two Dsz monooxygenases and, hence, to design an efficient BDS. Moreover, our results highlight the importance of reducing the HBPS release to the extracellular medium due to the impossibility of its further uptake by the bacterial cells. This previously unrecognized bottleneck will reduce the conversion of DBT into 2HBP when using whole cell biocatalysts. All these previously unanticipated limitations should be taken into consideration when designing efficient DBT bioconversion processes.
To overcome some of these limitations, we have engineered for the first time the 4S enzymatic steps as independent synthetic cassettes that are functional both alone and by combination. Our work revealed that generating an artificial 4S pathway by combining the dszC1-D1 and dszB1A1-D1 cassettes in an optimized synthetic bacterial consortium, and the dszB1 cassette as a cell-free extract, is a new and promising alternative to the use of naturally existing or recombinant dsz pathways for enhanced conversion of DBT into 2HBP. The compartmentalization of the monooxygenasedependent steps of the 4S pathway for DBT desulfurization in two different cell biocatalysts and their further combination to generate an artificial bacterial consortium constitutes a successful strategy toward the efficient conversion of DBT into the high added value HBPS compound. The in vitro evolution or isolation of new Dsz enzymes (Coco et al., 2001; Kamali et al., 2010 ) not susceptible to the inhibitions caused by the 4S intermediates are future challenges that should be taken into consideration for enhancing DBT bioconversions.
As far as we know, this work represents the first example of using synthetic consortia (Bacchus and Fussenegger, 2013; Du et al., 2013; Kalyuzhnaya et al., 2015; Ortiz-Marquez et al., 2014; Zargar et al., 2015) to compartmentalize the 4S pathway into different hosts for individual optimization, and for demonstrating that through division of labor, synthetic consortia can overcome process limitations difficult to achieve when using monocultures. Since the dsz cassettes reported here have been engineered in broad-host range plasmids, they can be tested and optimized in a wide range of potential gram-negative biocatalysts of predictable metabolic background and that can survive operating conditions in bioreactors, which makes them appealing as valuable genetic tools for DBT bioconversions in microbial cell factories (Sauer and Mattanovich, 2012 ).
This new strategy will facilitate further improvements of the BDS process to achieve the target desulfurization efficiencies (1-3 mmol 2HBP /g DCW/h) that have been reported to be needed for industrial applications (Kilbane, 2006 
